Health · Medical Research · 2 hrs ago

Wegovy trial finds lower BMI in children aged 6 to under 12

Wegovy trial finds lower BMI in children aged 6 to under 12

Novo reported results from a late-stage Wegovy trial involving children aged 6 to under 12 with obesity.

After 68 weeks, children who stayed on the drug had an average BMI decrease of 17.4%, while the placebo group’s BMI rose 2.2%.

All 167 children also received diet and activity changes during the trial.

Wegovy is approved for obesity in children aged 12 and older, but no medication is approved for obesity in children under 12.

Novo said the drug’s safety and tolerability were consistent with adult trials, with no observed concerns about growth or puberty.

The two-year study leaves long-term effects unclear, and Novo said more research is needed on treatment as children grow into adulthood.

3 sources

Related

What people are saying

Dr. Andrea TrainaNovo medical director lead of obesity
This is a very significant disease burden in this very young patient population
via CNBC
We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early
via CNBC
That is something that is still an evidence gap
via CNBC